SWK Holdings Corporation 9.00% Senior Notes due 2027 (SWKHL)
Full history for every metric is available with a Kvantra account
SWK Holdings Corporation 9.00% Senior Notes due 2027 (SWKHL)
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 37 | 56 | 41 | 38 | 45 | 41 | 41 | 39 |
| Operating profit | $m | 24 | 24 | ||||||
| Net profit | $m | 5 | 26 | 13 | 16 | 13 | -3 | -3 | - |
| EPS reported | $ | -0.21 | -0.22 | ||||||
| Operating cashflow per share | $ | 2.24 | 2.24 | ||||||
| Capex per share | $ | 0.04 | 0.03 | ||||||
| FCF per share | $ | 2.20 | 2.20 | ||||||
| Free cash flow | $m | 27 | 27 | ||||||
| Net debt | $m | -11 | -11 | ||||||
| Book value equity | $m | 235 | 235 | ||||||
| Book value per share | $ | 19.33 | 19.33 | ||||||
| Number of shares | m | 12.16 | 12.16 | ||||||
| DPS (TTM paid) | $ | 2.25 | 2.25 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.89 | 0.89 | ||||||
| P/S LTM | x | 5.13 | 5.13 | ||||||
| P/FCF LTM | x | 7.81 | 7.81 | ||||||
| EV/EBITDA LTM | x | 7.91 | 7.90 | ||||||
| EV/Sales LTM | x | 4.87 | 4.46 | ||||||
| Earnings Yield LTM | % | -1.21% | -1.31% | ||||||
| FCF Yield | % | +12.80% | +12.80% | ||||||
| Quality | |||||||||
| ROE | % | -1.08% | -0.99% | ||||||
| ROIC | % | -1.13% | -1.13% | ||||||
| Operating margin | % | +58.94% | +58.94% | ||||||
| Gross margin | % | +95.30% | +95.30% | ||||||
| FCF/Sales | % | +65.69% | +65.69% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -9.40% | -9.40% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | +16.86% | +16.86% | ||||||
| Operating Profit Growth | % | +107.35% | +107.35% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +23.46% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | -1921.6% | -1831.3% | ||||||
| FCF/Debt | x | 0.83 | 0.83 | ||||||
| Net Debt/EBITDA | x | -0.42 | -0.42 | ||||||
| EBIT/Net interest | x | 5.01 | 5.01 | ||||||
| Net debt/market cap | % | +15.35% | +16.70% | ||||||
| Net debt/Equity | x | -0.05 | -0.05 | ||||||
| Gross debt/equity | x | 0.14 | 0.14 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
SWK Holdings Corporation, established in Dallas, Texas, in 1996, is a specialized financial institution primarily focused on the healthcare sector. The company's activities are organized into two core divisions: Finance Receivables and Pharmaceutical Development. Through its Finance Receivables segment, SWK delivers tailored funding solutions to a broad range of entities within the life sciences industry. This client base includes firms in biotechnology, medical devices, medical diagnostics, animal health, and pharmaceuticals, as well as various institutions and individual innovators. Additionally, this division provides non-discretionary investment advisory services, overseeing separate accounts for institutional clients interested in life science investments. The Pharmaceutical Development division is involved in the full spectrum of drug creation, encompassing development, formulation, manufacturing, and intellectual property licensing, notably leveraging its proprietary Peptelligence platform. A central aim for this division is to out-license its internal pipeline of products, utilizing its distinct technological expertise to develop innovative treatments designed to enhance outcomes for patients and caregivers. The company was previously known as Kana Software, Inc., before officially rebranding as SWK Holdings Corporation in December 2009.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
SWK Holdings Corporation 9.00% Senior Notes due 2027 (SWKHL)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
SWK Holdings Corporation, established in Dallas, Texas, in 1996, is a specialized financial institution primarily focused on the healthcare sector. The company's activities are organized into two core divisions: Finance Receivables and Pharmaceutical Development. Through its Finance Receivables segment, SWK delivers tailored funding solutions to a broad range of entities within the life sciences industry. This client base includes firms in biotechnology, medical devices, medical diagnostics, animal health, and pharmaceuticals, as well as various institutions and individual innovators. Additionally, this division provides non-discretionary investment advisory services, overseeing separate accounts for institutional clients interested in life science investments. The Pharmaceutical Development division is involved in the full spectrum of drug creation, encompassing development, formulation, manufacturing, and intellectual property licensing, notably leveraging its proprietary Peptelligence platform. A central aim for this division is to out-license its internal pipeline of products, utilizing its distinct technological expertise to develop innovative treatments designed to enhance outcomes for patients and caregivers. The company was previously known as Kana Software, Inc., before officially rebranding as SWK Holdings Corporation in December 2009.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free